61 results about "Calcium channel blocker" patented technology

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are compositions comprising (1) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), a calcium channel blocker, and a sodium channel blocker and (2) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), and a sodium channel blocker, and uses of such compositions for stabilizing components in a blood sample.

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, wherein the dose of each component is below the lowest dose approved for the treatment of hypertension for the component.

This disclosure relates to methods of treating, e.g., complex regional pain syndrome (CRPS) using dual N-type and L-type calcium channel blockers selective for the N-type calcium channel (e.g., cilnidipine).

Provided herein are pharmaceutical compositions useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic and a calcium channel blocker. These compositions are administered at a dose of 40-80% of the lowest hypertensive therapeutic dose (LHTD) per agent. The present application also relates to a composition comprising telmisartan, a thiazine-like diuretic and a calcium channel blocker, administered at a dose of from 80 to 150% of the LHTD of each agent.

To provide a pharmaceutical composition for use in a method of treating a cancer in a subject.SOLUTION: The present invention provides a pharmaceutical composition for use in a method of treating a cancer in a subject, comprising at least one calcium channel blocker, wherein the method includes the steps of: (1) applying an alternating electric field to the target region in the subject for a predetermined time and (2) administering the pharmaceutical composition to the subject.SELECTED DRAWING: Figure 3

This article provides a pharmaceutical composition for the treatment of hypertension, comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Methods are provided to prevent and to treat diabetic retinopathy by using Calcium channel blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or angiotensin receptor blockers (ARB), and more particularly, to a method to prevent and treat diabetic retinopathy by using calcium channel blockers, Angiotensin-Converting Enzyme Inhibitors, or angiotensin receptor blockers that may not need to be taken orally, but may also be administered by ophthalmic preparation directly onto or into the eye where diabetic retinopathy is formed, to increase the capillary network and augment the blood supply to the anatomy of the eye.

The present invention provides cilnidipine, nilvadipine, isradipine, felodipine, verapamil, nimodipine or nifedipine, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment or prophylaxis of Attention Deficit / Hyperactivity Disorder (ADHD). The invention also provides kits and methods for the treatment or prophylaxis of ADHD.

The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.

The invention relates to application of epihevetide in preparation of a medicine for treating heart failure, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, by applying the pihepatolide to a zebra fish model and evaluating the influence of the pihepatolide on the heart failure induced by the non-dihydropyridine calcium channel blocker (verapamil), the fact that the pihepatolide can reverse the zebra fish heart failure induced by the verapamil is found for the first time, and the pihepatolide has obvious anti-heart failure treatment activity and small toxic and side effects. Candidates can be provided for anti-heart failure drugs, and the application has wide market prospects.

Provided herein are compositions comprising (1) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), a calcium channel blocker, and a sodium channel blocker and (2) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), and a sodium channel blocker, and uses of such compositions for stabilizing components in a blood sample.

Provided herein are pharmaceutical compositions useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic and a calcium channel blocker. These compositions are administered at a dose of 40-80% of the lowest hypertensive therapeutic dose (LHTD) per agent. The present application also relates to a composition comprising telmisartan, a thiazine-like diuretic and a calcium channel blocker, administered at a dose of from 80 to 150% of the LHTD of each agent.

The present invention is related to methods of treating cardiac arrhythmia, angina, or a migraine in a patient in need thereof, with a therapeutically effective amount of a compound having a structure according to the formula:the method comprising nasally administering to the patient (i) a first dose, and (ii) a second dose of an aqueous composition comprising a pharmaceutically acceptable acetate or methanesulfonate salt of compound I, or a racemate or enantiomer thereof, wherein the acetate or methanesulfonate salt of compound I, or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of 350 mg / mL±50 mg / mL, and wherein the second dose of the compound is administered between 5 minutes and 25 minutes after the first dose.

The present invention concerns the use of an L-type calcium channel (LTCC) blocker in combination with a BRAF inhibitor (BRAFi) and / or a MEK inhibitor (MEKi) for the treatment of melanoma in a patient.

Provided herein are methods and compositions for the treatment of hearing impairment by administering a combination of two or more calcium channel blockers.

A pharmaceutical composition comprising azilsartan medoxomil potassium and a calcium channel blocker, a method for preparing same, and use thereof are provided. Azilsartan medoxomil potassium and the calcium channel blocker are formulated into a compound formulation, thus improving the blood pressure lowering efficacy, improving safety and tolerability, and reducing adverse effects. Azilsartan medoxomil potassium can ameliorate peripheral edema caused by amlodipine by means of expanding peripheral venous vessels, while amlodipine can ameliorate adverse effects such as vasogenic edema, dry cough, and the like caused by azilsartan medoxomil potassium.

Provided herein are pharmaceutical compositions comprising a class of calcium channel blockers and at least one chelating agent. More specifically, the pharmaceutical compositions comprise at least one 1,4-dihydropyridine (DHP) compound and at least one chelating agent. The chelating agents used in this disclosure can decrease the degradation of the constituent DHPs of the DHP compositions. The DHP compositions can be used to treat cardiovascular disorders and are more stable for prolonged periods of time.

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

The present invention provides a pharmaceutical composition containing azilsartan medoxomil potassium and a calcium channel blocker, as well as a method for preparing and using the same. The development of a combination formulation using azilsartan medoxomil potassium and a calcium channel blocker is advantageous in terms of improving antihypertensive effects, improving safety and tolerability, and reducing side effects. Azilsartan medoxomil potassium can alleviate amlodipine-induced peripheral edema by dilating peripheral venous blood vessels, while amlodipine can alleviate adverse reactions such as angioedema and dry cough caused by azilsartan medoxomil potassium. Compared with single drugs, the advantages of combination drugs include: (1) reducing medication dosage and improving patient compliance; (2) improving compliance for elderly people and those with dysphagia; and (3) preventing frequent fluctuations in blood drug concentrations, maintaining stable blood drug concentrations, stabilizing blood pressure in hypertensive patients over the long term, and reducing the side effects of each drug. (4) Avoid patients discontinuing medication on their own, and prevent disease recurrence and progression of malignant complications.

The invention discloses application of an L-type calcium channel blocker as a ferroptosis inhibitor in preparation of drugs, and belongs to the technical field of biological medicines. In order to solve the problem that an effective acute pancreatitis and organ injury treatment means is lacked in the prior art, the invention provides application of an L-type calcium channel blocker as a ferroptosis inhibitor in preparation of a medicine for preventing / treating acute pancreatitis and organ injury, and the L-type calcium channel blocker is Benidipine, Xinidipine or Manidipine; proved by detection such as western blot and the like, the L-type calcium channel blocker can inhibit activation of ferroptosis key protein and generation of intracellular lipid active oxygen, is high in safety and provides a new means for disease treatment.

A reduction in viability of cancer cells (e.g., glioblastoma) and a reduction in tumor volume can be achieved by applying a 100-500 kHz (e.g., 200 kHz) alternating electric field to the cancer cells and inhibiting IL11 (interleukin-11) activity and optionally administering and anti-fibrotic agent. The inhibiting of IL11 activity may be accomplished, for example, by decreasing IL11 expression, inhibiting IL11 signaling, downregulating IL11, neutralizing IL11, blocking an IL11 receptor, administering an IL11 antagonist, administering an IL11 neutralizing antibody, or administering an IL11 receptor a (IL11Ra) neutralizing antibody.